Search

Randomized Phase IIa Clinical Trial Of Cyclosporine For The Treatment Of COVID-19(+) Non-ICU Hospital Inpatients (H-48163)
healthcare › clinical-trials › h-48163
… inpatients will be randomized 2:1 to 7 days of an oral formulation of cyclosporine, Neoral  (2.5mg/kg PO BID) … on the World Health Organization (WHO) COVID Ordinal Outcomes Scale, on day 14. Secondary endpoints include safety and changes in serum inflammatory markers.   …
Phase I/II Study of Niraparib with Radiotherapy for Treatment of Metastatic Invasive Carcinoma of the Cervix (H-40404)
healthcare › clinical-trials › h-40404
… The most effective strategy for managing distantly metastatic invasive carcinomas of the … ovarian cancer trials and the concern for toxicities and comorbidities limiting the compliance of concurrent … to determine the maximum tolerated dose and to evaluate the safety, tolerability and preliminary efficacy of niraparib, …
Adaptation and Evaluation of SHARE: A Self-Management Intervention for Head and Neck Cancer Patients and their Caregivers (H-38984)
healthcare › clinical-trials › h-38984
… website throughout the duration of their radiation therapy (6-8 sessions). One month post-treatment, patients and …
MFMU Study: A Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation With a Short Cervix (PROSPECT) (H-53697)
healthcare › clinical-trials › h-53697
… cervical length is known to be an important risk factor for spontaneous preterm birth and to occur more frequently … reduces the risk of prematurity in singleton gestations complicated with a short cervix. This protocol outlines a … MFMU Study: A Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation With a Short Cervix …
A031803: Testing the Addition of Pembrolizumab to Gemcitabine for BCG-Unresponsive Non-muscle Invasive Bladder Cancer (H-50373)
healthcare › clinical-trials › h-50373
… may delay the return of BCG-unresponsive bladder cancer for longer period compared to gemcitabine alone. For more information: … Testing the Addition of Pembrolizumab to Gemcitabine for BCG-Unresponsive Non-muscle Invasive Bladder Cancer …
Summer Science Institute
community › educational-outreach › summer-science-institute
… explore the scientific phenomenon for themselves in safe, exciting way while getting content and a legitimate …
Recurrent Head and Neck Cancer
healthcare › ... › recurrent-head-neck-cancer
… loss can be signs that a cancer may have returned. Regular visits and open discussions of your symptoms after therapy, … cutting-edge clinical trials and have experience with the latest chemotherapeutic agents, immunotherapy and targeted … clinical trials that give participants access to the latest, most comprehensive diagnostic and treatment options …
Quantitative & Computational Biosciences Interview Information
education › ... › interview-information
… Thank you for applying to the Quantitative & Computational Biosciences Graduate Program at Baylor College of Medicine … require to determine if the Quantitative & Computational Biosciences Graduate Program at BCM is the right fit for … Ph.D. Director, Program in Quantitative and Computational Biosciences amilosav@bcm.edu Jenna Brown …
Amyotrophic Lateral Sclerosis
healthcare › ... › amyotrophic-lateral-sclerosis
… clinical trials that give participants access to the latest, most comprehensive diagnostic and treatment options …
Meet Our Team: Ear, Nose and Throat
healthcare › ... › meet-our-team
… College of Medicine pediatric otolaryngology specialist, visit Texas Children's Ear, Nose and Throat (Otolaryngology) …